Ritonavir & Lopinavir Suppliers & Bulk Manufacturers
Available Forms: Tablet and Oral Solution
Available Strengths: Tab: Lopinavir 200 mg + Ritonavir 50 mg; oral solution:80 mg / 20 mg per mL
Reference Brands: Kaletra(US & EU)
Category:
Anti Viral
Lopinavir & Ritonavir Tablets (Kaletra®) combine two protease inhibitors for HIV treatment. Available in 200/50 mg strength, they are sourced via PharmaB2B platforms from WHO-GMP-approved manufacturers. Perfect for bulk procurement, tenders, and public health programs ensuring global access to essential HIV medicines.
Ritonavir & Lopinavir is available in Tablet and Oral Solution
and strengths such as Tab: Lopinavir 200 mg + Ritonavir 50 mg; oral solution:80 mg / 20 mg per mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Ritonavir & Lopinavir is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Ritonavir & Lopinavir can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Lopinavir & Ritonavir Tablets, widely marketed as Kaletra®, are a fixed-dose combination of two protease inhibitors used in the treatment of HIV-1 infection. Each tablet typically contains Lopinavir 200 mg and Ritonavir 50 mg, with Ritonavir boosting the effectiveness of Lopinavir. This antiretroviral combination remains vital in HIV care, especially in resource-limited settings and global treatment programs. PharmaB2B platforms connect global buyers, NGOs, and procurement agencies with WHO-GMP and USFDA-approved manufacturers offering bulk supply at competitive rates. Ideal for tenders and institutional supply, this therapy supports consistent, affordable access to HIV medications worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing